| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/17/2009 | US20090232805 Methods of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist |
| 09/17/2009 | US20090232804 Humanized antibodies specific for von willebrand factor |
| 09/17/2009 | US20090232803 Antibodies to human il-1beta |
| 09/17/2009 | US20090232802 Compositions and methods for the treatment of natural killer cell related diseases |
| 09/17/2009 | US20090232801 Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
| 09/17/2009 | US20090232800 E1-minus adenoviruses and use thereof |
| 09/17/2009 | US20090232799 Antibodies that bind urokinase-type plasminogen activator and epitopes therefor |
| 09/17/2009 | US20090232798 Methods and compositions for treating herpes infections |
| 09/17/2009 | US20090232797 Plasmodium malariae and plasmodium ovale genes and uses thereof |
| 09/17/2009 | US20090232796 Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand |
| 09/17/2009 | US20090232795 1b20 pcsk9 antagonists |
| 09/17/2009 | US20090232794 Modulators of neuronal regeneration |
| 09/17/2009 | US20090232793 Elastase inhibitor and acute leukemia |
| 09/17/2009 | US20090232766 Compositions for Inducing Immune Response Comprising Inverted Microsomes |
| 09/17/2009 | US20090232737 Purification of proteins |
| 09/17/2009 | US20090232736 Dual specificity antibodies and methods of making and using |
| 09/17/2009 | US20090232735 Use of fructose-based therapies for the treatment of cancer |
| 09/17/2009 | US20090232734 Anti-tissue factor antibodies and compositions |
| 09/17/2009 | US20090232733 Diagnostic and Therapeutic Potential of Immune Globulin Intravenous (IGIV) Products |
| 09/17/2009 | US20090232732 PRO108 Antibody Compositions and Methods of Use and Use of PRO108 to Assess Cancer Risk |
| 09/17/2009 | US20090232730 Method of producing immunoliposomes and compositions thereof |
| 09/17/2009 | CA2718878A1 Compositions and methods for the therapy and diagnosis of cytomegalovirus |
| 09/17/2009 | CA2718495A1 Recombinant production of authentic human proteins using human cell expression systems |
| 09/17/2009 | CA2718381A1 Immuno-modulating compositions for the treatment of immune-mediated disorders |
| 09/17/2009 | CA2718289A1 Anti-tyrp1 antibodies |
| 09/17/2009 | CA2717997A1 Fusion protein with directioning of vaccinal antigens toward antigen-presenting cells and the applications thereof |
| 09/17/2009 | CA2717870A1 Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use |
| 09/17/2009 | CA2717812A1 Agent for treating disease |
| 09/17/2009 | CA2717499A1 Replication-defective flavivirus vaccines and vaccine vectors |
| 09/17/2009 | CA2717221A1 Reagents and methods for detecting influenza virus proteins |
| 09/17/2009 | CA2716919A1 An anti-cd6 monoclonal antibody and use thereof |
| 09/16/2009 | EP2100960A2 Specific polypeptides and nucleic acids of pathogenic strains of the Neisseria genus |
| 09/16/2009 | EP2100955A2 Attenuated mutants of human parainfluenza virus type 1 (HPIV1) |
| 09/16/2009 | EP2100903A2 Anti-idiotypic antibodies neutralising the inhibiting activity of an inhibiting antibody directed against domain C1 of factor VIII |
| 09/16/2009 | EP2100902A1 Methods for treating pain by administering an antagonist antibody against the nerve growth factor and an opioid analgesic, and compositions containing the same |
| 09/16/2009 | EP2100620A1 Nucleic acids encoding polyepitope polypeptides |
| 09/16/2009 | EP2100619A1 Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| 09/16/2009 | EP2100618A2 PDGFR-alpha antagonists for treatment of metastatic bone cancer |
| 09/16/2009 | EP2100617A1 Methods of modulating CD200 receptors |
| 09/16/2009 | EP2100616A2 Composition of antigen and glycolipid adjuvant sublingual administration |
| 09/16/2009 | EP2100615A1 Cancer therapy |
| 09/16/2009 | EP2100614A2 PDGFR-alpha antagonists for treatment of metastatic bone cancer |
| 09/16/2009 | EP2099927A2 Methods of reducing porcine circovirus-associated disease outbreaks |
| 09/16/2009 | EP2099827A2 Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| 09/16/2009 | EP2099826A1 Method of providing disease-specific binding molecules and targets |
| 09/16/2009 | EP2099824A2 Enterococcus faecalis and/or enterococcus faecium antigen |
| 09/16/2009 | EP2099823A2 Variant target binding agents and uses thereof |
| 09/16/2009 | EP2099494A2 Multivalent pneumococcal polysaccharide-protein conjugate composition |
| 09/16/2009 | EP2099491A2 Compositions and methods for diagnosing and treating cancer |
| 09/16/2009 | EP2099490A1 New drug for inhibiting, preventing or treatment of rheumatoid arthritis |
| 09/16/2009 | EP2099489A2 Compositions and methods for treating a neoplasm |
| 09/16/2009 | EP2099488A1 Tslp vaccine for the treatment of th2 mediated inflammatory conditions |
| 09/16/2009 | EP2099487A2 Process for manufacturing vaccines |
| 09/16/2009 | EP2099486A2 Codon modified immunogenic compositions and methods of use |
| 09/16/2009 | EP2099485A1 Alphavirus and alphavirus replicon particle formulations and methods |
| 09/16/2009 | EP2099484A1 Treatment of prdc in pigs |
| 09/16/2009 | EP2099483A1 Immunization protocol against the 4 dengue serotypes |
| 09/16/2009 | EP2099482A2 Chlamydia pneumoniae vaccine and methods for administering such a vaccine |
| 09/16/2009 | EP2099481A1 Vaccin against group a beta hemolytic streptococcus and respective process for obtaining thereof |
| 09/16/2009 | EP2099480A2 Microorganisms of fractions thereof capable of activating cellular immunity against carbohydrates |
| 09/16/2009 | EP2099479A2 Salmonella vaccine in poultry |
| 09/16/2009 | EP2099478A2 Means and method for raising improved immune response |
| 09/16/2009 | EP2099470A1 Use of mage a3-protein d fusion antigen in immunotherapy combined with surgery, chemotherapy or radiotherapy for the treatment of cancer |
| 09/16/2009 | EP2099414A2 Human antibodies that bind human il-12 and methods for producing |
| 09/16/2009 | EP1638599B1 Vaccine composition for vaccinating dogs against canine infectious respiratory disease (cird) |
| 09/16/2009 | EP1542732B1 Fusion proteins of mycobacterium tuberculosis |
| 09/16/2009 | EP1519748B1 Microparticle with cd28-specific monoclonal antibodies |
| 09/16/2009 | EP1438583B1 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays |
| 09/16/2009 | EP1414948B1 Inhibition of apoptosis process and improvement of cell performance |
| 09/16/2009 | EP1379273B1 Nucleic acid adjuvants |
| 09/16/2009 | EP1349568B1 Immunomodulatory constructs and their uses |
| 09/16/2009 | EP1343814B1 Immunogenic glycopeptides, screening, preparation and uses |
| 09/16/2009 | EP1324776B1 Reduced-viscosity concentrated protein formulations |
| 09/16/2009 | EP1223978B9 Archaeosomes as adjuvants and carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses |
| 09/16/2009 | EP1169021B1 Compositions and methods for treating lymphoma |
| 09/16/2009 | EP1126878B1 Heparanase activity neutralizing anti-heparanase monoclonal antibody |
| 09/16/2009 | EP1027443B1 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 09/16/2009 | CN101534861A Polyalkylene oxides having hindered ester-based biodegradable linkers |
| 09/16/2009 | CN101534860A Compositions and methods using anti-CS1 antibodies to treat multiple myeloma |
| 09/16/2009 | CN101534859A Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 09/16/2009 | CN101534858A Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 09/16/2009 | CN101534857A Cancerous disease modifying antibodies |
| 09/16/2009 | CN101534856A Quality control methods for oil-in-water emulsions containing squalene |
| 09/16/2009 | CN101534855A Vaccine |
| 09/16/2009 | CN101534854A 疫苗 Vaccine |
| 09/16/2009 | CN101532030A Recombinant influenza virus vector carrying foreign genes in NA segment and preparation method and application thereof |
| 09/16/2009 | CN101531720A Streptavidin/green fluorescent fusion protein |
| 09/16/2009 | CN101531718A Anti-VEGFR-2 antibody chimeric Fab antibody fragment, preparation method and application thereof |
| 09/16/2009 | CN101531717A Anti-Alzheimer disease monoclonal antibody and application thereof |
| 09/16/2009 | CN101530616A Vaccine adjuvant and vaccine composition |
| 09/16/2009 | CN101530615A Divalent recombinant human papilla virus vaccine |
| 09/16/2009 | CN101530614A Pentavalent recombinant human papilla virus vaccine |
| 09/16/2009 | CN101530613A Infectious spleen and kidney necrosis virus vaccine and preparation method and application thereof |
| 09/16/2009 | CN101530612A Type-16 recombinant human papilla virus vaccine |
| 09/16/2009 | CN101530395A Method for preparing LTB-carboxymethyl chitosan influenza vaccine intranasal immunization microspheres |
| 09/16/2009 | CN100541198C Methods for diagnosis and therapy of cancer and composition useful therein |
| 09/16/2009 | CN100540058C Use of IL-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases |
| 09/16/2009 | CN100540053C New clinical parameters for determining hematologic toxicity proior to radioimmunotherapy |
| 09/16/2009 | CN100540052C Allergy vaccine composition, production method thereof and use of same in allergy treatment |
| 09/16/2009 | CN100540051C Modified vaccinia virus ankara for the vaccination of neonates |